Giannoni M, Pollastro M, Jacobellis M
Consultorio Familiare U.S.L. n. 8, Genova Ponente.
Minerva Med. 1990 Jul-Aug;81(7-8):555-9.
The therapeutic efficacy and tolerability of the antifungal agent ciclopiroxolamine have been verified with a double-blind study versus clotrimazole in 46 patients affected by vulvovaginal candidiasis. The patients of the first group (23) have been treated with ciclopiroxolamine globules, one 100 mg globule nightly for six days; the second group (23 patients) received clotrimazole vaginal tablets, one 200 mg tablet nightly for six days. Ciclopiroxolamine treatment showed an equivalent effectiveness to that of clotrimazole both on signs and symptoms and on vaginal smear culture. No local or systemic adverse reaction was observed.
通过一项针对46例外阴阴道念珠菌病患者的双盲研究，已证实抗真菌药物环吡酮胺与克霉唑相比的治疗效果和耐受性。第一组（23例）患者接受环吡酮胺滴丸治疗，每晚1粒100毫克滴丸，共6天；第二组（23例患者）接受克霉唑阴道片治疗，每晚1片200毫克片剂，共6天。环吡酮胺治疗在体征、症状及阴道涂片培养方面显示出与克霉唑等效的疗效。未观察到局部或全身不良反应。
